biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > BTI:TSXV; BIOAF:OTCQB - Positive Results: xB3™-IL-1RA of MS

<< Previous

Bullboard Posts

Next >>

Comment by MineDiggeron Jul 08, 2021 5:45am

162 Views

Post# 33510679

RE:BTI:TSXV; BIOAF:OTCQB - Positive Results: xB3™-IL-1RA of MS

Nice to see something positive, but does anyone else wonder about what we're not beig told, like the actual name of the study, who ran it, how much difference the treatment made (ie more detail than "delayed onset and overall reduced ")?

And I can't scan the sentence "Since IL-1 cytokines have been implicated in many autoimmune and neuroinflammatory diseases, xB³™-IL-1RA was investigated disease in the rodent experimental allergic encephalomyelitis (EAE) model of multiple sclerosis"

Does it make sense to anyone else?

MD

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta